These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 28392453)
1. Physiologically Based Pharmacokinetic Modeling of Therapeutic Proteins. Wong H; Chow TW J Pharm Sci; 2017 Sep; 106(9):2270-2275. PubMed ID: 28392453 [TBL] [Abstract][Full Text] [Related]
2. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. Shah DK; Betts AM J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Dostalek M; Gardner I; Gurbaxani BM; Rose RH; Chetty M Clin Pharmacokinet; 2013 Feb; 52(2):83-124. PubMed ID: 23299465 [TBL] [Abstract][Full Text] [Related]
4. A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim. Niederalt C; Kuepfer L; Solodenko J; Eissing T; Siegmund HU; Block M; Willmann S; Lippert J J Pharmacokinet Pharmacodyn; 2018 Apr; 45(2):235-257. PubMed ID: 29234936 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn. Chen Y; Balthasar JP AAPS J; 2012 Dec; 14(4):850-9. PubMed ID: 22956476 [TBL] [Abstract][Full Text] [Related]
6. Physiologically based pharmacokinetic models of small molecules and therapeutic antibodies: a mini-review on fundamental concepts and applications. Ferl GZ; Theil FP; Wong H Biopharm Drug Dispos; 2016 Mar; 37(2):75-92. PubMed ID: 26461173 [TBL] [Abstract][Full Text] [Related]
7. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity? Gurbaxani B; Dostalek M; Gardner I Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469 [TBL] [Abstract][Full Text] [Related]
8. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. Garg A; Balthasar JP J Pharmacokinet Pharmacodyn; 2007 Oct; 34(5):687-709. PubMed ID: 17636457 [TBL] [Abstract][Full Text] [Related]
9. Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model. Li L; Gardner I; Dostalek M; Jamei M AAPS J; 2014 Sep; 16(5):1097-109. PubMed ID: 25004823 [TBL] [Abstract][Full Text] [Related]
10. Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development. Glassman PM; Balthasar JP Drug Metab Pharmacokinet; 2019 Feb; 34(1):3-13. PubMed ID: 30522890 [TBL] [Abstract][Full Text] [Related]
11. Computer-assembled cross-species/cross-modalities two-pore physiologically based pharmacokinetic model for biologics in mice and rats. Sepp A; Meno-Tetang G; Weber A; Sanderson A; Schon O; Berges A J Pharmacokinet Pharmacodyn; 2019 Aug; 46(4):339-359. PubMed ID: 31079322 [TBL] [Abstract][Full Text] [Related]
12. Application of FcRn binding assays to guide mAb development. Datta-Mannan A; Wroblewski VJ Drug Metab Dispos; 2014 Nov; 42(11):1867-72. PubMed ID: 25024401 [TBL] [Abstract][Full Text] [Related]
13. Physiologically based pharmacokinetic (PBPK) model that describes enhanced FcRn-dependent distribution of monoclonal antibodies (mAbs) by pI-engineering in mice. Naoi S; Yamane M; Nemoto T; Kato M; Saito R; Tachibana T Drug Metab Pharmacokinet; 2023 Dec; 53():100506. PubMed ID: 38029470 [TBL] [Abstract][Full Text] [Related]
14. Development and Application of a Physiologically-Based Pharmacokinetic Model to Predict the Pharmacokinetics of Therapeutic Proteins from Full-term Neonates to Adolescents. Pan X; Stader F; Abduljalil K; Gill KL; Johnson TN; Gardner I; Jamei M AAPS J; 2020 May; 22(4):76. PubMed ID: 32449129 [TBL] [Abstract][Full Text] [Related]
15. Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model. Varkhede N; Forrest ML J Pharm Pharm Sci; 2018; 21(1s):130s-148s. PubMed ID: 30011390 [TBL] [Abstract][Full Text] [Related]
16. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. Jones HM; Chen Y; Gibson C; Heimbach T; Parrott N; Peters SA; Snoeys J; Upreti VV; Zheng M; Hall SD Clin Pharmacol Ther; 2015 Mar; 97(3):247-62. PubMed ID: 25670209 [TBL] [Abstract][Full Text] [Related]
17. Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model. Chetty M; Li L; Rose R; Machavaram K; Jamei M; Rostami-Hodjegan A; Gardner I Front Immunol; 2014; 5():670. PubMed ID: 25601866 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of the whole body physiologically based pharmacokinetic (WB-PBPK) modeling of drugs. Munir A; Azam S; Fazal S; Bhatti AI J Theor Biol; 2018 Aug; 451():1-9. PubMed ID: 29704489 [TBL] [Abstract][Full Text] [Related]
19. Translational two-pore PBPK model to characterize whole-body disposition of different-size endogenous and exogenous proteins. Liu S; Li Y; Li Z; Wu S; Harrold JM; Shah DK J Pharmacokinet Pharmacodyn; 2024 Oct; 51(5):449-476. PubMed ID: 38691205 [TBL] [Abstract][Full Text] [Related]
20. Physiologically based pharmacokinetic (PBPK) modeling and simulation: applications in lead optimization. Peters SA; Ungell AL; Dolgos H Curr Opin Drug Discov Devel; 2009 Jul; 12(4):509-18. PubMed ID: 19562647 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]